---
schema_version: "secwatch.filing_event.v1"
accession: "0001079973-23-000239"
form_type: "8-K/A"
ticker: null
cik: "0001602078"
company_name: "Nemaura Medical Inc."
filed_at: "2023-02-22T23:59:59+00:00"
generated_at: "2026-06-19T04:55:09.365724+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Nemaura Medical restates Q1 and Q2 FY2022 financials; net loss decreased by up to $313k

## Summary
- Non-reliance on Q1 and Q2 FY2022 10-Qs due to errors in foreign currency translation and debt issuance costs.
- Net loss for Q1 FY2022 decreased by $90k to ~$3.889M; Q2 FY2022 decreased by $223k to ~$3.856M; six months decreased by $313k to ~$7.745M.
- Material weakness in internal controls over financial reporting identified; disclosure controls not effective.
- Q3 FY2022 10-Q (for period ended Dec 31, 2022) expected to be delayed beyond Feb 21, 2023 deadline.
- Errors do not impact previously reported sales, gross profit, or cash positions.

## SEC filing metadata
- accession: 0001079973-23-000239
- form_type: 8-K/A
- cik: 0001602078
- company_name: Nemaura Medical Inc.
- filed_at: 2023-02-22T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 4.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1602078/000107997323000239/0001079973-23-000239-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1602078/000107997323000239/nmra_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001079973-23-000239
- JSON: https://secwatch.observer/filing/0001079973-23-000239.json
- Plain text: https://secwatch.observer/filing/0001079973-23-000239.txt

## Key facts
- Auditor Changes
  Nemaura Medical Inc. reported that prior financial statements should not be relied upon.
  - Action: non reliance
  source text: On February 17, 2023, the management and the Audit Committee of the Board of Directors of Nemaura Medical, Inc. (the “Company”) concluded that the following financial statements should be restated and should no longer be relied upon:
  evidence_url: https://www.sec.gov/Archives/edgar/data/1602078/000107997323000239/0001079973-23-000239-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.